Analyses were conducted on four pharmaceutical compounds, representing different therapeutic classes, to evaluate the presence and potential adverse human health effects of trace levels of these substances in aqueous environmental media. Acetylsalicylic acid, clofibrate, cyclophosphamide, and indomethacin have been detected in aqueous environmental media including sewage treatment plant effluent, surface water, drinking water, and groundwater. An extensive literature search and chemical-specific risk assessments were performed to assess the potential human health significance of each compound's individual presence in environmental media. Safe water quality limits were estimated for each pharmaceutical by following the USEPA Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health and were compared to the concentrations found in the environment. The calculation of the provisional ambient water quality criteria involved estimation of human exposure to contaminated water, including intake via bioaccumulation in fish, and calculation of cancer risk and non-cancer hazard indices. Parameters detailing the toxicological and pharmacological nature, exposure assessment, and environmental fate and transport of each pharmaceutical were also considered. The overall conclusion was that based on available data, no appreciable risk to humans exists, as the detected concentrations of each of these pharmaceutical compounds found in aqueous media were far below the derived safe limits.
INTRODUCTION
A number of studies have detected trace levels of some pharmaceuticals in various environmental media; however, there have been few attempts to assess the potential human health-related significance of their presence. This paper will summarize the environmental occurrence of four pharmaceutical compounds and examine the potential human health risks.
First studied in Europe in the 1970s, pharmaceuticals have been measured in trace levels in sewage effluent and with generally diminishing concentrations, in surface water, groundwater, and drinking water. Pharmaceutical compounds are introduced into the environment through a number of different pathways, including excretion of the parent compound, active ingredients, water soluble conjugates, or metabolites via urine and feces after therapeutic home and hospital use, and through disposal of unused pharmaceuticals by patients or providers via landfills and sewers (Ayscough et al. 2000) . Data indicate that the pharmaceuticals detected in aqueous environmental media have sustained passage through typical sewage treatment processes, as a result of incomplete removal. Consequently, evidence of drug residues in receiving waters has emerged (Ternes 1998) . Studies by Heberer and Stan (1996a,b; 1997 , Hignite and Azarnoff (1977) , Stan et al. (1994) , Stan and Heberer (1997) , Stumpf et al. (1996 Stumpf et al. ( , 1999 , Ternes (1998 Ternes ( , 1999 and Ternes et al. (1998) , among others, have identified and measured a variety of human pharmaceuticals including hormones, lipid regulators, pain killers, antibiotics, anti-cancer drugs, anti-epileptic drugs, and blood pressure drugs at a range of concentrations, most below 1 µg/l.
The present study has three objectives. First, a review of the literature regarding the range of concentrations detected in aqueous environmental media (sewage effluent, surface water, groundwater, and drinking water). Secondly, to calculate water quality limits for each pharmaceutical using U.S. Environmental Protection Agency (USEPA) methodology, and third, to evaluate the potential for human health risks due to chronic exposures of each of these pharmaceuticals in drinking water and/or surface water.
APPROACH
Chemical-specific risk assessments were performed on each of four pharmaceutical compounds (acetylsalicylic acid , clofibrate (CAS 637-07-0), cyclophosphamide (CAS 50-18-0), and indomethacin (CAS 53-86-1) to assess the potential human health significance of their individual presence in various aqueous environmental media. The compounds chosen for this study were selected based on a review of published literature regarding pharmaceuticals detected in aqueous environmental media, then narrowed down to compounds representing different therapeutic drug classes that have been found more commonly or at the higher end of the spectrum of measured concentrations. The pharmaceutical compounds selected for this study fall into the following drug classes: analgesic, lipid regulator, cytotoxic/anticancer, and anti-inflammatory drugs (one of which, acetylsalicylic acid, is sold over the counter).
To estimate a safe water quality limit for each pharmaceutical of interest, USEPA's recently published Methodology for Deriving Ambient Water Quality Criteria for the Protec-Pharmaceuticals in the Aquatic Environment tion of Human Health (USEPA 2000) was used to calculate provisional ambient water quality criteria (AWQC) . The values serve as benchmarks by which the measured concentrations of these pharmaceuticals in the environment can be compared.
One goal of this methodology is the development of numeric values limiting the amount of chemicals present in surface waters of the United States in order to be protective of human health, with these limits based on human health toxicity criteria. The procedure evaluated cancer risk and non-cancer health effects through an evaluation of human exposure, including the bioaccumulation potential of each pharmaceutical in fish that could subsequently be ingested. The proposed AWQCs were calculated from health-based limits (HBLs) derived for each of the compounds using the following equations:
For noncancer effects: AWQC = HBL * RSC * (1/DI + (FI * BAF)))
For linear cancer effects: AWQC = RSD * (BW/(DI + (FI * BAF)))
where: AWQC = Ambient Water Quality Criterion (mg/L); HBL = Health Based Limit for noncancer effects (mg/day); RSD = Risk-specific dose for linear carcinogens (mg/kg-day)(Dose associated with a target risk of 10 -5 ); RSC = Relative source contribution factor to account for non-water sources of exposure (in this case all exposure is from water sources therefore = 100%); BW = Human body weight (default = 70 kg for adults); DI = Drinking water intake (default = 2L/day for adults); FI = Fish intake (defaults = 0.0178 kg/day for general population and sports anglers, and 0.039 kg/day for subsistence fishers); BAF = Bioaccumulation factor, lipid normalized (L/kg) The limits are expressed using a generic term, (HBL), so as to not be confused with equivalent specific regulatory limits such as reference dose (RfD) and acceptable daily intake (ADI). The basis for each of the HBLs is summarized below.
HAZARD IDENTIFICATION/DOSE-RESPONSE ASSESSMENT Acetylsalicylic Acid
Acetylsalicylic acid (ASA) or aspirin is a human and veterinary over-the-counter medicine that is a non-steroidal anti-inflammatory also used for its analgesic, antipyretic and anti-coagulating properties. ASA is a white crystalline powder that is odorless but has a slightly bitter taste. It has a molecular weight of 180.15, a melting point of 132 to 136°C, a pKa of 3.49, a log Kow of 1.19 and is soluble in water at 4.6 × 103 mg/L (ACGIH 1996).
ASA is not acutely toxic by the oral route, with reported oral LD50s of 1.5 g/kg and 1.1 g/kg in rats and mice, respectively. ASA is known to cause skin, eye and upper respiratory tract irritation upon direct contact and gastrointestinal bleeding following chronic ingestion. The majority of toxicity information on ASA is from effects following oral exposure, however it is also known to be absorbed rectally. Salicylates are also absorbed through intact skin. ASA is a known systemic allergen and can produce anaphylaxis at doses in the lowest end of the therapeutic range (10 mg/kg). Although ASA has low acute toxicity, significant toxicity may result from single oral doses above 300 to 500 mg/kg, and doses of 10 to 30 grams have caused fatalities in adults and a dose of 5 grams (roughly 6 low-dose ASA tablets/ kg) has caused fatalities in children (NLM 2001) .
In non-human toxicity studies, significant species variability in response to ASA has been shown due to different rates of metabolism. ASA is negative in a series of mutagenicity and clastogenicity assays (Jasiewicz and Richardson 1987; NLM 2001) . Animal studies have shown that ASA is teratogenic in rats (Beall and Klein 1977; Kimmel et al. 1974; Davis et al. 1996) . Teratogenicity is thought to be due to the hydrolysis product, salicylic acid (Koshakji and Schulert 1973) . The lowest LOAEL was shown to be 10 mg/kg/day for 2 to 3 days. This dose given to rats orally on days 19-21 of gestation caused a delay in parturition, and increased fetal deaths. Aspirin however is commonly consumed during pregnancy and does not appear to be a human teratogen (Reprotext System 2001) . ASA has been given to prevent certain complications of pregnancy such as pre-eclampsia, at doses ranging from 60 to 150 mg/day (AHFS 2000) . No adverse effects were seen at 18 months in children of mothers taking 60 mg/day for pre-eclampsia (Farrell et al. 1995) .
There is no evidence that ASA is a human carcinogen and strong epidemiological evidence suggests that it can afford protection from some cancers (Garcia Rodriguez and Huerta-Alvarez 2001) . In animals, ASA given to rats in the diet at 0.5% for 68 weeks was not carcinogenic (Johansson et al. 1986 ).
The vast majority of the information on the chronic effects of ASA is derived from therapeutic ingestion or chronic overdose. ASA exerts its therapeutic effects by inhibition of both isoforms of the cyclooxygenase (COX-1 and COX-2) enzyme and subsequently the production of prostaglandins. The inhibition of COX-1 is largely responsible for the gastrointestinal irritation, bleeding and ulcers associated with NSAID use. ASA also inhibits platelet aggregation through inhibition of thromboxane A2 and prostacyclin and therefore is useful as an anticoagulant and for the prevention of thrombosis (AHFS 2000) . Typical chronic therapeutic doses of ASA vary depending on the condition being treated. The usual dose range for anticoagulant therapy ranges from 30 to 150 mg/day (AHFS 2000) . For post-surgical prevention of thrombosis, prevention of myocardial infarction, and reduction of risk for myocardial infarction in angina patients, the typical dose range is 75 to 325 mg/day (AHFS 2000) . Treatment for pain ranges from 650 to 1,300 mg/day and for treatment of rheumatic disease, it is 5000 to 6000 mg/day (AHFS 2000) . A 50% reduction in risk of colorectal cancer becomes evident after 6 months of continuous ASA use at 300 mg/day. An increased risk of upper gastrointestinal bleeding is seen at doses of 325 mg/day or less. ASA is contraindicated in patients with hemophilia, gout or those with aspirin intolerance. The most common side effects of aspirin therapy include nausea, dyspepsia, and vomiting. Ulceration, hematemesis and melena may also occur (Martindale 1993) .
Approximately 80 to 100% of an oral dose of ASA is absorbed. Following oral administration, ASA is nearly completely (99%) hydrolyzed to salicylic acid either in the gastric mucosa or by tissue esterases. Salicylic acid and other salicylate metabolites such as salicyluric acid, phenolic salicylate, acyl glucuronides and gentisic acid are excreted in the urine. The plasma half-life is 15 to 20 minutes (AHFS 2000).
A health-based limit of 1 mg/day is established based on a LOEL of 30 mg/day for the low end of the dose range for anticoagulant therapy. This is also a NOEL for the endpoint of therapeutic closure of the ductus arteriosus in human infants. The
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HBL assumes an uncertainty factor of 3 to account for the use of a LOEL to estimate a NOEL and an uncertainty factor of 10 to account for interindividual variability. The current ACGIH Threshold Limit Value (TLV  ) and OSHA Permissible Exposure Limit (PEL) for acetylsalicylic acid is 5 mg/m 3 as an 8-hour time-weighted average. This was deemed low enough to prevent workers from experiencing effects on clotting time and platelet aggregation as well as gastric and respiratory irritation. The TLV/PEL would translate into a HBL of 50 mg assuming the average worker breathes 10 m 3 of air in an 8-hour workday. From this it would appear that the calculated HBL would be at least an order of magnitude more conservative.
Clofibrate
Clofibrate is an effective antihyperlipidemic agent that reduces serum levels of triglyceride-rich, very low-density lipoproteins (VLDL) and, to a lesser extent, cholesterol-rich, low density lipoproteins (LDL). It also lowers serum free fatty acids. The exact mechanism by which clofibrate lowers serum concentrations of triglycerides and cholesterol is unknown. Clofibrate is a colorless to pale yellow liquid, which has a characteristic faint odor and taste. It is known chemically as 2-(4-chlorophenoxy)-2-methyl-propanoic acid ethyl ester and has a molecular weight of 242.7, and a boiling point of 148 to 150°C at 20 mmHg. It is practically insoluble in water (Merck Index 1996) . The ester is easily hydrolyzed and is sensitive to oxidation and light (NLM 2001) .
In non-human toxicity studies, significant rodent-specific variability in response to clofibrate has been shown due to differences in the extent of peroxisome proliferation. Consequently, rodents are not an appropriate model for extrapolating the effects of clofibrate in humans due to their greater susceptibility to lipid peroxidation.
Reproduction studies in both dogs and monkeys using clofibrate dosages approximately 4 to 6 times the usual human dosage have demonstrated arrest of spermatogenesis (AHFS 1995) .
Clofibrate is not classifiable as to its carcinogenicity in humans based on inadequate evidence (IARC-Group 3), although limited evidence of carcinogenicity exists in experimental animals (IARC 1996) .
The recommended dose of clofibrate is 2 grams daily in 2 to 4 divided doses. The lowest clinically active dose is 500 mg/day (Perlemuter et al. 1975) . Clofibrate is contraindicated in patients with known hypersensitivity to the drug, in pregnant and nursing women, and in patients with hepatic or renal dysfunction and primary biliary cirrhosis. The most common undesirable effects include nausea, headache, dizziness, fatigue, drowsiness, weakness, breast tenderness in men, fever, dry skin, brittle hair, alopecia, rash, pruritus, toxic epidermal necrolysis, and erythema (AHFS 2000) . It is absorbed from the gastrointestinal tract rapidly and almost completely. Maximum plasma concentrations occur at about 4 to 6 hours after oral administration. It is rapidly hydrolyzed to the acid by tissue and serum esterases. The majority (95-99%) of an orally administered dose is excreted in urine as free and conjugated clofibric acid, (2-(4-chlorophenoxy) isobutyric acid). Clofibric acid is the therapeutically active metabolite of clofibrate. The majority of plasma drug is protein-bound. Clofibric acid has an elimination half-life of 12 to 35 hours (mean 12 to 22 hours) (AHFS 2000).
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Cyclophosphamide
Cyclophosphamide is a nitrogen mustard derivative, polyfunctional alkylating agent. Drugs of this class are also called synthetic anti-neoplastics or chemotherapeutic drugs and are used in the treatment of numerous myeloproliferative and lymphoproliferative disorders and solid malignancies. Cyclophosphamide functions as an alkylating agent following biotransformation to a phosphoramide mustard in the body. It interferes with DNA replication and transcription of RNA resulting in the disruption of nucleic acid function. It has marked phosphorylating properties, which enhances its toxicity and also confers potent immunosuppressive activity (AHFS 2000) . Cyclophosphamide has also been tested as an insect chemosterilant and for use in chemical sheep shearing (IARC 1981) . The compound is a fine white crystalline powder known chemically as N, N-Bis (2-chloroethyl) tetrahydro-2H-1, 3,2-oxa-phosphorin-2-amine, 2-oxide monohydrate with a molecular weight of 279.1 (IARC 1981) . It is soluble in water at 4 × 10 4 mg/L (Howard and Meylan 1997) .
Occupationally, cyclophosphamide exposure occurs via inhalation, dermal contact and ingestion, while therapeutically it is given by injection. The oral LD 50 of cyclophosphamide in mice and rats is 137 and 160 mg/kg, respectively (NLM 2001) . Cyclophosphamide is embryotoxic and teratogenic in mice, rats, rabbits and rhesus monkeys at dosages as low as 2.5 mg/kg/day (Shepard 1992; McClure et al. 1979) . Damage was produced to DNA in spermatozoa from adult male rats exposed to 6.1 mg/kg/day for 1 or 6 weeks (Qui et al. 1995) . According to the International Agency for Research on Cancer, there is sufficient evidence for the carcinogenicity of cyclophosphamide in experimental animals (IARC 1981) . Malignant tumors have been produced in rats and mice following oral, subcutaneous, intramuscular, and intraperitoneal administration.
The recommended oral dosage of cyclophosphamide for treatment of various cancers is 1 to 5 mg/kg of body weight daily for adults or 10 to 15 mg/kg administered intravenously every 7 to 10 days. It is well absorbed via the oral route and has greater than 75% bioavailablity. Maximum plasma concentrations occur at about 1 hour and concentrations of metabolites reach maximum levels 2 to 3 hours after an intravenous dosage. Cyclophosphamide is excreted primarily in the urine with about 36 to 99% of a dose eliminated within 48 hours. The mean plasma half-life is 5 hours. The most common undesirable short-term health effects include cough or hoarseness, fever or chills, lower back or side pain, missed menstrual periods, painful urination, darkening of skin and fingernails, loss of appetite, nausea or vomiting, hair loss, blood in urine, dizziness, confusion or agitation, fast heartbeat, joint pain, shortness of breath, swelling of feet or lower legs, and unusual tiredness or weakness (Medlineplus 2001) . Cyclophosphamide has been shown to be a human carcinogen based on studies from patients administered the drug for treatment of cancer (Green et al. 1986) . Approximately 5% of patients receiving cumulative doses ranging from 7.6 to more than 30 grams developed secondary malignancies some years after treatment for cancer.
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The critical endpoint for deriving a health-based value for cyclophosphamide is cancer. The State of California, under Proposition 65 legislation (CEPA 1993) , has used the rat bladder tumor data from Schmahl and Habs (1979) to calculate a cancer slope factor of 0.57 (mg/kg/day) -1 . The corresponding no-significant-risk level (NSRL) is 1 µg/day (1 × 10 -5 excess cancer risk). A risk specific dose (RSD) of 0.000014 mg/kg/day was derived using the NSRL of 1 µg/day published by the State of California. The risk associated with the RSD is within the range of the risk levels of 10 -4 to 10 -6 recommended by the USEPA for drinking water. No adverse effects on organ systems or the developing fetus are expected at this level of exposure (i.e., protecting against cancer should protect against all other adverse effects).
Indomethacin
Indomethacin is a pale yellow to yellow-tan crystalline powder that may have a slight odor or is odorless, and has a slightly bitter taste. It is designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. Its molecular weight is 357.79. One form of polymorphic indomethacin crystals has a melting point of about 155°C, the other of about 162°C. Indomethacin has a pKa of 4.50, a log K ow of 4.27 at a pH of 2.0. It is practically insoluble in water at 9.37 × 10 -1 mg/ L (Merck Index 1996) .
Indomethacin is a prescription medication that is a member of the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs) that is also used for its antipyretic and analgesic properties. In addition, the drug is used to treat tocolysis (premature labor) and polyhydramnios (excess amniotic fluid) in pregnant women (Lione and Scialli 1995) . In premature infants, intravenous administration of indomethacin is the conventional pharmacological treatment used to promote closure of patent ductus arteriosus (PDA) (Van Overmeire et al. 2000) .
The doses of indomethacin tolerated by experimental animals, particularly the dog and rat, are lower than those tolerated in man. The primary toxic effect of indomethacin in experimental animals is ulceration of the gastrointestinal tract. Indomethacin is also known to cause vascular irritation (thrombophlebitis) when given intravenously at high doses. The oral LD 50 (14-day observation period) of indomethacin in rats, mice, and dogs was 12, 50, and 160 mg/kg, respectively. In addition, low maternal dosing (0.5 mg/kg) of pregnant ewes has been shown to be lethal to fetuses (Lione and Scialli 1995) . As a result of these species differences, it is inappropriate to base a quantitative evaluation of indomethacin for human health on animal data.
In oncogenicity tests in rats and mice, indomethacin produced no neoplastic or hyperplastic changes related to treatment at doses up to 1.5 mg/kg/day (Medical Economics Company 2000) .
Indomethacin was not genotoxic in a battery of in vitro (with or without metabolic activation) or in vivo tests. In teratogenicity studies, indomethacin administered to mice and rats at a dose of 4.0 mg/kg/day during the last 3 days of gestation resulted in decreased maternal weight gain and some maternal and fetal deaths (Medical Economics Company 2000) . At this dose, live-born fetuses had an increased incidence of neuronal necrosis in the diencephalon. At a dose of 2.0 mg/kg/day, no increase in neuronal necrosis occurred, or if administered postnatally at doses up 200521.pgs 6/14/02, 2:01 PM 663 to 4.0 mg/kg/day (Medical Economics Company 2000) . Approximately 99% of indomethacin is bound to plasma proteins (Rane et al. 1978; The Pharmaceutical Press 2001) . Indomethacin crosses the human placenta, and maternal and fetal serum concentrations are similar (Moise et al. 1990 ). The medication is excreted into breast milk, with a milk:plasma ratio reported to be near 1:1, based on only a single study (Eeg-Olofsson et al. 1978) . The American Academy of Pediatrics has classified indomethacin as being compatible with breastfeeding (Committee on Drugs -American Academy of Pediatrics 1994).
The recommended clinical dosage for anti-inflammation and/or analgesia is one 25 mg or 50 mg capsule, two or three times daily (i.e., 50 to 150 mg/day) (AHFS 2000) . Thus, the minimum therapeutic dose is approximately 0.71 mg/kg/day. The maximum daily dose is 150 to 200 mg/day, or 4 mg/kg/day, whichever is less (Medical Economics Company 2000) . Orally administered indomethacin is virtually 100% bioavailable, with 90% of the dose absorbed within 4 hours. Symptoms with greater than 1% incidence associated with indomethacin use are gastrointestinal complaints, central nervous system complaints, and tinnitus (Medical Economics Company 2000).
Paradoxically, while use of NSAIDs in the third trimester, has been associated with a dramatic but potentially reversible increase in adverse effects on the fetus (precipitated by the premature constriction or closure of the ductus arteriosus) (Vermillion et al. 1997) , indomethacin is also used during pregnancy to treat tocolysis (premature labor) and polyhydramnios (excess amniotic fluid) in pregnant women (Lione and Scialli 1995) . There may only be transitory changes in a variety of target organs (e.g., kidney [Ojala et al. 2001a ], gastrointestinal or respiratory tracts (Vermillion and Newman 1999) , cerebral blood flow [Parilla et al. 1997 ], intraventricular hemorrhage), with no increase in fetal death [Vermillion and Newman 1999] ).
In the premature infant, indomethacin is a standard medication used for treatment of refractory closure of the patent ductus arteriosus (PDA). PDA increases an infant's risk of intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, and death. There is some evidence that post-natal treatment of PDA with indomethacin may increase risk of transient or permanent renal dysfunction, necrotizing enterocolitis, gastrointestinal hemorrhage, and reduced cerebral intracellular oxygenation (Van Overmeire et al. 2000) . Follow-up studies have not reported any adverse neurobehavioral effects of prophylactic low-dose indomethacin use in low-birth-weight infants through age 36 months (Couser et al. 2000) , nor increased risk of esophageal and gastric lesions (Ojala et al. 2001b) . The association of indomethacin treatment, either pre-or perinatally, with a variety of serious adverse health outcomes, including death, may be confounded by a variety of issues, including the small, often non-randomized study populations, the high-risk for myriad adverse outcomes faced by preterm births in general, and by the concomitant risk factors that may predispose these infants to adverse outcomes (e.g., multiple medical procedures and medications).
Indomethacin inhibits platelet aggregation and may prolong bleeding time. However, unlike ASA, indomethacin is a reversible inhibitor of prostaglandin synthestase and recovery of platelet function may occur within 1 day after discontinuation of the medication (Medical Economics Company 2000).
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The critical endpoint for deriving a health-based value for indomethacin is the inhibition of prostaglandin synthesis. A health-based limit (HBL) of 1.67 mg/day was derived based on a subtherapeutic dose of 37.5 mg/day resulting in inhibition of platelet aggregation in a small percentage of patients (Rane et al. 1978) . This LOEL was then adjusted downward with a default 30-fold composite uncertainty factor to account for the use of a LOEL to estimate a NOEL and interindividual variability. Note that this value provides a wide margin of safety over clinical doses used to treat pregnant women in the third trimester for premature labor, and thus should be protective of the fetus since no significant cyclooxygenase inhibition would be anticipated at such a low dose.
From an environmental exposure standpoint, the extremely low water solubility of indomethacin (0.937 mg/L; [NLM 2001] ) limits risk to the general public. Consider the risk posed to the fetus of a pregnant woman in her third trimester. On average, pregnant women consume 1.19 L/day of tap water, with a 95 th percentile value of 2.4 L/day (USEPA 2000) . Even assuming indomethacin were present at its water solubility limit, her average intake would be only about 1 mg/day, nearly 40-fold lower than the lowest subtherapeutic dose associated with platelet inhibition, and nearly 200-fold lower than the dose used to treat tocolysis that is associated with adverse outcomes in only a fraction of the exposed population. At the 95 th percentile of tapwater intake, her intake would be only about 2.2 mg/day, nearly 15fold lower than the lowest subtherapeutic dose, and nearly 91-fold lower than the dose used to treat tocolysis.
EXPOSURE ASSESSMENT
In addition to the establishment of the HBL and the RSD values, it was also necessary to derive a bioaccumulation factor (BAF) for each pharmaceutical and the metabolites, where relevant, based on each compound's behavior in the environment. The log K ow values were obtained from the literature for acetylsalicylic acid, salicylic acid, clofibric acid, cyclophosphamide, and indomethacin (NLM 2000; Hansch et al. 1995) . The log K ow for clofibrate was estimated using the online log K ow estimation program (KowWin) from the Syracuse Research Corporation since an experimental value was not available (Syracuse Research Corporation 2001) . The bioaccumulation calculations were then completed based on the ionic status of each pharmaceutical according to USEPA methodology. Since the log K ow for each pharmaceutical compound was below four, suggesting negligible bioaccumulation, the bioaccumulation simplified to a bioconcentration factor normalized for lipid, which is equivalent to the log K ow (USEPA 2000) . However, because actual bioconcentration factors (BCF) were provided in the literature for cyclophosphamide and acetylsalicylic acid (NLM 2000) , these values were used to account for BAF. Since no empirical BCF values were available for indomethacin, clofibrate, clofibric acid, and salicylic acid, the log K ow values were used to calculate BCFs following USEPA methodology (see Tables 1 and 2) .
These variables served as inputs into the USEPA methodology, along with the assumption of 100% for relative source contribution (RSC), that is, attributing 100% of the exposure of these pharmaceuticals to ingestion of contaminated drinking water (or surface water) or fish versus other sources. This reflects the assumption that no other exposures are likely to occur unless an individual is being treated at therapeutic doses many orders of magnitude greater than likely environmental exposures. USEPA default values for body weight, fish intake, and average drinking water intake were also used in the calculation of the AWQC.
In an effort to understand and assess any potential risk to human health, the concentrations of pharmaceuticals detected in the environment were compared with the derived water quality limits. This comparative analysis was limited to concentrations of each pharmaceutical detected in surface water and drinking water only, and was not completed for those pharmaceuticals measured in sewage effluent and groundwater. Surface water was included since it is may be used as a drinking water supply or may be incidentally ingested during recreational activity.
RESULTS
Health-based limits (HBLs) were established for each pharmaceutical classified as a non-carcinogen (acetylsalicylic acid, clofibrate, indomethacin), while a risk specific dose (RSD) was established for cyclophosphamide based on its carcinogenic classification. The results are shown in Table 2 along with the following criteria, which support the establishment of these levels: critical endpoint, NOEL/LOEL, and uncertainty factors, or RSD. The calculation of an AWQC according to EPA methods, for each pharmaceutical compound, was based on the corresponding HBL or RSD and the (BAF), which are also displayed in Table 2 . For the three noncarcinogenic pharmaceuticals, the HBLs shown are within an order of magnitude of each other and therefore the corresponding AWQCs are fairly close as well. Acetylsalicylic acid and clofibrate are both metabolized to pharmacologically active molecules, which have been shown to be present in the environment. In the case of clofibrate, the acid metabolite has a much lower BAF than the parent compound and therefore the corresponding AWQC is an order of magnitude higher. For cyclophosphamide, the risk associated with the RSD corresponding to 10 -5 excess cancer risk is within the range of the risk levels of 10 -4 to 10 -6 as recommended by the USEPA.
A compilation of all of the studies whose findings show measured concentrations of each pharmaceutical compound detected in the environment, according to the specific media in which they were found, either sewage effluent, surface water, groundwater, and/or drinking water are seen in Tables 3 through 6. The concentrations in bold type represent the maximum level detected in each particular medium for each compound. The data are presented for each pharmaceutical (parent compound and/or its metabolites where measured) detected in each of these environmental media, along with the number of samples taken (when given), limit of detection (LOD), country of sampling, and the corresponding reference indicating the original researcher(s) and year of study.
Acetylsalicylic acid, salicylic acid, clofibric acid, cyclophosphamide, and indomethacin have been detected in sewage effluent and surface water, while clofibric acid was additionally detected in groundwater and drinking water. Clofibrate has been detected in surface water only. Generally, the concentrations detected for the parent compounds are less than 1 µg/L, except for acetylsalicylic acid where detections have been recorded up to 3.1 µg/L. It should also be noted that while individual characteristics of the environmental media are not provided in this analysis, the pharmaceuticals examined have been detected in waters from a number of countries as shown in Tables 3 through 6.
In order to be conservative in an assessment of potential risk, the maximum concentration detected in the environmental medium most likely to be a drinking water source was used in a comparison to the calculated AWQC, as shown in Table  7 . Average, maximum, and/or 90 th percentile pharmaceutical concentrations detected in either surface water and/or drinking water are also shown. Since no information was provided on water treatment, it was assumed that surface water could be consumed directly without further treatment. In order to evaluate potential human health risk, maximum detected concentrations were compared to their respective calculated AWQC values. Of the four pharmaceutical compounds studied, none of them indicate an appreciable risk to human health based on the fact that the measured concentrations in surface and/or drinking water are all significantly below the derived AWQC. It should also be noted that the pharmaceutical compounds which were not detected in the environment (as indicated by ND) in Table 7 (acetylsalicylic acid in drinking water, clofibrate in drinking water, cyclophosphamide in surface water, and indomethacin in drinking water) do not present any appreciable risk either, especially since the limits of detection (LOD) for each of these compound falls within the range of 5 to 10 ng/L, which is significantly below the provisional AWQC for all of the compounds. In addition, it should be noted that detection limits are likely to decrease in the future, as more sensitive analytical detection techniques become available.
DISCUSSION
The main finding of this study was that detected levels of the compounds of interest (parent compounds, acetylsalicylic acid, clofibrate, cyclophosphamide, and indomethacin, as well as the metabolites, salicylic acid and clofibric acid) in surface waters and drinking water, do not pose a risk to human health. The concentrations of each of these pharmaceuticals found in various environmental media to date, fall well below the provisional safe water quality limits derived, according to the AWQC methodology. Thus, no adverse health effects for humans are anticipated from the levels measured.
These results were influenced in large part by the derivation of the HBL according to the LOEL/NOEL and uncertainty factors. Incidentally, it should be noted that the terms, lowest-observed effect level/no-observed-effect level (LOEL/NOEL) and the lowest-observed-adverse effect level/no-observed-adverse-effect level (LOAEL/NOAEL), are synonymous in this kind of instance, as any biological effect whether therapeutic or adverse as a result of an environmental exposure is considered undesirable. In general, when establishing threshold for pharmaceuticals, consideration must be given to not only therapeutic effects but also to adverse (side) effects and the potential for idiosyncratic reactions or hypersensitivity as well. In order to account for the apparent areas of uncertainty in the data sets for each compound, the USEPA's guidelines for the establishment of uncertainty factors were followed by identifying and classifying the uncertainties into the following categories as seen in 
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to NOELs (USEPA 2000) . The uncertainty factors were then combined to generate a composite uncertainty factor (UF C ) by which the LOEL is divided to establish the HBL and ultimately, the AWQC.
A review of the data reflects on average, approximately a one order of magnitude reduction in concentrations between each medium, from sewage effluent to surface water, surface water to groundwater, and groundwater to drinking water. This effect coincides with the expected dilution and removal effect, respectively, that occurs once sewage effluent is discharged into surface water and once surface water or groundwater undergoes drinking water treatment.
It is noted that the maximum observed groundwater concentration recorded for clofibric acid from a single study in Germany is actually higher than that found in surface water by an order of magnitude, which is not consistent with the pattern noted above. This phenomenon may be due in part to a number of factors. For one, while it is known that clofibric acid is highly mobile and persistent in the environment (Buser et al. 1998) , this sample appears to be unusual and may simply be an exception to the previously noted trend. It is also known that in Germany where these samples were collected, surface water is often extracted from groundwater wells adjacent to rivers for drinking water production. Therefore, the contamination of clofibric acid in groundwater may originate from contaminated surface water, as well as from releases from septic systems and other terrestrial sources directly to groundwater. Furthermore, the literature reveals that the particularly high concentrations of clofibric acid (7300 ng/l) may have been due in part to the contributions from an additional point source in the area, in this case an unused former chemical plant .
While our results provide useful information regarding the establishment of safe levels of these pharmaceuticals for surface water and drinking water according to USEPA methodology, it is possible that the measured concentrations typical in Europe as a result of sewage treatment and drinking water technologies may differ from those found in the United States. Since the United States has not conducted extensive research in this area to date, we relied primarily on European data reflecting detected levels of pharmaceuticals in their environment to compare with derived USEPA water quality limits, or AWQCs. In the future, it would be worthwhile to compare the results of typical concentrations found in the United States, perhaps using the recently published U.S. Geological Survey's Reconnaissance Study (Kolpin et al. 2002) .
The provisional AWQC derived in these analyses were established as concentrations of the pharmaceuticals of interest in the environment that will protect the general population from adverse health effects. Since the concentrations detected in the environment are many orders of magnitude below the typical therapeutic doses and because uncertainty factors are used to account for interindividual variability, sensitive subpopulations would also not be adversely impacted. This fact also accounts for the belief that there is no additional risk presented to patients already taking prescribed, therapeutic doses of these pharmaceuticals as the additional dose received via drinking water or surface water has been determined to be negligible and without appreciable risk.
Any such comprehensive risk assessment is complicated due to the potential additive, antagonistic, or synergistic nature of drug interactions. This assessment, however, was 200521.pgs 6/14/02, 2:01 PM 675 carried out as a chemical specific risk assessment for each compound in an effort to evaluate each pharmaceutical individually. It does not account for the potential impacts on human health due to exposure to mixtures or combination of drugs or pollutants.
This study is one of the first few attempts at a human health risk assessment of pharmaceuticals in the environment. Our findings, however, must be interpreted with caution in view of the limited existing data and the methodology. While this study analyzes the risk to humans, it does not examine the ecological effects that trace levels of pharmaceutical compounds may have on flora or fauna residing in or consuming potentially contaminated drinking water sources. These potential effects are considered in the United States, however, during an initial assessment of risk to the environment of manufacture, use, and distribution of human drugs under regulations promulgated by the U.S. Food and Drug Administration pursuant to the National Environmental Policy Act of 1969 (GPO 2001 ). An environmental assessment procedure, as carried out in the United States, assesses the expected introductory concentration (EIC) of a new drug entering the environment, based on total fifth year production estimates. If the EIC in the aquatic environment is less than 1 µg/L (1 ppb), an environmental categorical exclusion is granted, as the drug residue is deemed acceptable. However, if the EIC is greater than 1 µg/L, a formal environmental assessment must be conducted, requiring the collection and submittal of environmental fate and ecotoxicity testing data. A similar environmental risk assessment procedure evaluating predicted environmental concentrations (PEC) against a threshold and to predicted no-effect concentrations (PNEC), is followed in Europe (Ayscough et al. 2000) .
Because the issue of pharmaceuticals in the environment is a fairly new one, the number of data sets available are few in number, and the spectrum of analytes limited to the parent drug and not the metabolites or conjugates of the parent drug. Consequently, it was only possible to evaluate data from a limited number of investigations conducted for each compound. Additionally, it should be noted that data indicating environmental significance of pharmaceuticals in various media has proven to be even rarer, making it more difficult to assess ecological health. However, as analytical techniques become more sophisticated in the future and more numerous samples are collected and analyzed for a broader array of pharmaceuticals, it would be important to reevaluate the implications of low-level concentrations of pharmaceuticals detected in the environment.
